Immediate Impact

5 from Science/Nature 59 standout
Sub-graph 1 of 23

Citing Papers

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
2025 Standout
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
2024 Standout
2 intermediate papers

Works of Emre Yıldırım being referenced

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events
2020
Hepatogastroenterology
2011

Author Peers

Author Last Decade Papers Cites
Emre Yıldırım 226 93 170 149 29 631
J.B.M.J. Jansen 109 75 203 76 28 559
Sylvain Mukenge 122 55 147 108 24 723
Ulrika Smedh 69 54 207 93 38 689
Masako Yokoyama 134 53 190 66 40 699
Rehfeld Jf 182 172 219 37 27 654
Giuseppe De 241 40 178 35 29 669
A. P. Gokin 139 31 123 49 42 620
Isabel Silva 146 38 70 38 39 669
Evangelos Bozas 97 172 162 36 30 698
G. Lux 74 29 296 144 33 595

All Works

Loading papers...

Rankless by CCL
2026